Foundry Partners LLC Sells 2,135 Shares of Zoetis Inc. (ZTS)
Foundry Partners LLC decreased its position in Zoetis Inc. (NYSE:ZTS) by 17.2% during the second quarter, Holdings Channel reports. The firm owned 10,263 shares of the company’s stock after selling 2,135 shares during the period. Foundry Partners LLC’s holdings in Zoetis were worth $640,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently made changes to their positions in the company. Assetmark Inc. raised its position in Zoetis by 4.6% in the first quarter. Assetmark Inc. now owns 1,918 shares of the company’s stock worth $102,000 after buying an additional 85 shares during the period. Guardian Life Insurance Co. of America raised its position in Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock worth $102,000 after buying an additional 13 shares during the period. Point72 Asia Hong Kong Ltd bought a new position in Zoetis during the first quarter worth approximately $111,000. Advisory Services Network LLC bought a new position in Zoetis during the first quarter worth approximately $112,000. Finally, First Interstate Bank raised its position in Zoetis by 3.5% in the first quarter. First Interstate Bank now owns 2,250 shares of the company’s stock worth $120,000 after buying an additional 76 shares during the period. Institutional investors own 92.70% of the company’s stock.
Shares of Zoetis Inc. (NYSE:ZTS) opened at 60.90 on Friday. The firm has a 50 day moving average price of $62.00 and a 200-day moving average price of $58.20. Zoetis Inc. has a one year low of $46.86 and a one year high of $63.85. The firm has a market cap of $29.79 billion, a P/E ratio of 34.43 and a beta of 1.02.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, hitting the consensus estimate of $0.53. The firm had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The business’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.49 earnings per share. Analysts forecast that Zoetis Inc. will post $2.34 earnings per share for the current year.
WARNING: This story was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/08/18/foundry-partners-llc-sells-2135-shares-of-zoetis-inc-zts.html.
ZTS has been the topic of a number of recent research reports. Deutsche Bank AG restated a “buy” rating and set a $65.00 price objective (up previously from $62.00) on shares of Zoetis in a research note on Monday, July 17th. BMO Capital Markets restated a “buy” rating and set a $60.00 price objective on shares of Zoetis in a research note on Thursday, May 4th. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $67.00 price objective on the stock in a research note on Wednesday, May 10th. Argus restated a “buy” rating and set a $69.00 price objective (up previously from $60.00) on shares of Zoetis in a research note on Tuesday, May 30th. Finally, Hilliard Lyons initiated coverage on Zoetis in a research note on Tuesday, June 20th. They set a “buy” rating and a $77.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the stock. Zoetis presently has an average rating of “Buy” and an average price target of $64.78.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.